Abstract:AIM:Many studies reveal an association between the acquired chemoresistant phenotype of cancer cells and tumor-initiating cell-like properties. The aim of this study was to determine the impact of c-Jun N-terminal kinase (JNK) on the tumor-initiating cell-like properties of acquired chemoresistant human cancer cells.METHODS:Two well-established human acquired chemoresistant cancer cell lines K562/A02 and KB/VCR, as well as their respective parental counterparts K562 and KB were tested. The expression of relevant mRNAs and proteins was detected using qRT-PCR and Western blotting, respectively. Sphere formation and self-renewal assays were used to study the tumor-initiating cell-like properties. Soft agar and colony formation assays were used to investigate tumorigenic ability.RESULTS:We observed that suppressing JNK activity by its specific small molecule inhibitor SP600125 or by limiting JNK1/2 expression with JNK1/2 shRNA lentiviruses inhibited the expression of pluripotent stem cell markers such as Oct4, Sox2, and Nanog in KB/VCR cells and K562/A02 cells as well as sphere formation and self-renewal abilities of K562/A02 cells. Additionally, inhibition of JNK activity significantly inhibited the in vitro and in vivo tumor-initiating abilities of KB/VCR cells. Furthermore, our data suggest that blocking JNK activity abundantly inhibited the Hedgehog (Hh) pathway activity, as reflected by reduction of Hedgehog (Hh) pathway target genes Gli1 and ptch1 at the mRNA level as well as Gli-luciferase activity.CONCLUSION:JNK maintains the tumor-initiating cell-like properties of acquired chemoresistant K562/A02 and KB/VCR cells potentially through activating the Hedgehog pathway. Thus, disruption of tumor-initiating cell-like properties by targeting JNK may be a new approach to combating acquired chemoresistance.

NFAT3, a substrate of JNKs, is a negative regulator of Ras-JNK-induced cell transformation

Nuclear Factor Of Activated T3 Is A Negative Regulator Of Ras-Jnk1/2-Ap-1 - Induced Cell Transformation

Identification of a Human NF-κB-activating Protein, TAB3

NFAT3 is specifically required for TNF- -induced cyclooxygenase-2 (COX-2) expression and transformation of Cl41 cells

NF-κB is Required for H-ras Oncogene Induced Abnormal Cell Proliferation and Tumorigenesis

Cdk3-Mediated C-Jun Phosphorylation At Ser63 And Ser73 Enhances Cell Transformation

PTPN3 Acts As a Tumor Suppressor and Boosts TGF-β Signaling Independent of Its Phosphatase Activity.

Tissue Type-Specific Modulation of Er Transcriptional Activity by Nfat3

Data from Cyclin-Dependent Kinase-3–Mediated C-Jun Phosphorylation at Ser63 and Ser73 Enhances Cell Transformation

JNK-Dependent cJun Phosphorylation Mitigates TGFβ- and EGF-Induced Pre-Malignant Breast Cancer Cell Invasion by Suppressing AP-1-Mediated Transcriptional Responses.

NRF-1 Directly Regulates TFE3 and Promotes the Proliferation of Renal Cancer Cells.

Ras-Dependent, Ca2+-Stimulated Activation Of Nuclear Factor Of Activated T Cells By A Constitutively Active Cbl Mutant In T Cells

NFAT As Cancer Target: Mission Possible?

An Atypical E3 Ligase Zinc Finger Protein 91 Stabilizes and Activates NF-κB-inducing Kinase Via Lys63-linked Ubiquitination

Defective anchoring of JNK1 in the cytoplasm by MKK7 in Jurkat cells is associated with resistance to Fas-mediated apoptosis.

Recombinant NFAT1 (NFATp) is regulated by calcineurin in T cells and mediates transcription of several cytokine genes

NFATc3 Inhibits Hepatocarcinogenesis and HBV Replication Via Positively Regulating RIG-I-mediated Interferon Transcription.

Neurotrophin3 promotes hepatocellular carcinoma apoptosis through the JNK and P38 MAPK pathways

JNK is Required for Maintaining the Tumor-Initiating Cell-Like Properties of Acquired Chemoresistant Human Cancer Cells.

Repression of NFAT3 Transcriptional Activity by Estrogen Receptors.

Regulation of the Orphan Receptor TR3 Nuclear Functions by C-Jun N Terminal Kinase Phosphorylation